Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 17,442 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 17,442 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $66.97, for a total transaction of $1,168,090.74. Following the completion of the transaction, the chief executive officer now owns 316,744 shares in the company, valued at $21,212,345.68. The trade was a 5.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

William Lewis also recently made the following trade(s):

• On Wednesday, May 14th, William Lewis sold 3,771 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total value of $247,415.31.
• On Thursday, May 1st, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $72.57, for a total value of $495,653.10.
• On Tuesday, April 15th, William Lewis sold 6,830 shares of Insmed stock. The shares were sold at an average price of $70.16, for a total value of $479,192.80.
• On Monday, March 17th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.03, for a total value of $1,444,312.50.
• On Monday, March 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.79, for a total value of $1,458,562.50.
• On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50.

Insmed Trading Up 2.5%

Shares of INSM stock opened at $67.22 on Friday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $12.22 billion, a price-to-earnings ratio of -12.03 and a beta of 0.84. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The stock’s 50-day moving average price is $71.68 and its 200-day moving average price is $73.12.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million for the quarter, compared to analysts’ expectations of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.06) EPS. Equities research analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Insmed

Large investors have recently bought and sold shares of the business. Cullen Frost Bankers Inc. lifted its position in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 221 shares during the last quarter. Elequin Capital LP purchased a new stake in shares of Insmed during the 4th quarter valued at about $28,000. Steward Partners Investment Advisory LLC lifted its holdings in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 163 shares during the last quarter. V Square Quantitative Management LLC grew its position in Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 248 shares in the last quarter. Finally, Spire Wealth Management purchased a new position in Insmed in the fourth quarter worth about $47,000.

Wall Street Analyst Weigh In

INSM has been the topic of several analyst reports. Truist Financial lifted their price target on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a report on Friday, February 21st. Morgan Stanley raised their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $100.00 target price on shares of Insmed in a report on Wednesday, March 19th. Stifel Nicolaus decreased their price target on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Finally, Jefferies Financial Group initiated coverage on Insmed in a research report on Tuesday. They issued a “buy” rating and a $105.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $94.63.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.